Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
7.00
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)- Insider Own49.61% Shs Outstand37.47M Perf Week6.87%
Market Cap262.22M Forward P/E- EPS next Y-3.18 Insider Trans5.09% Shs Float18.60M Perf Month-9.68%
Income- PEG- EPS next Q-0.62 Inst Own28.37% Short Float3.82% Perf Quarter-42.62%
Sales- P/S- EPS this Y83.80% Inst Trans- Short Ratio5.32 Perf Half Y-
Book/sh7.36 P/B0.95 EPS next Y2.00% ROA- Short Interest0.71M Perf Year-
Cash/sh8.74 P/C0.80 EPS next 5Y- ROE- 52W Range5.50 - 12.74 Perf YTD-32.10%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-45.05% Beta-
Dividend TTM- Quick Ratio4.75 Sales past 5Y3569.20% Gross Margin- 52W Low27.27% ATR (14)0.62
Dividend Ex-Date- Current Ratio4.75 EPS Y/Y TTM- Oper. Margin- RSI (14)43.85 Volatility4.89% 9.56%
Employees236 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price16.83
Option/ShortNo / Yes LT Debt/Eq0.16 EPS Q/Q-329.49% Payout- Rel Volume0.39 Prev Close7.00
Sales Surprise42.02% EPS Surprise-42.11% Sales Q/Q127.13% EarningsMay 14 AMC Avg Volume133.43K Price7.00
SMA202.69% SMA50-21.87% SMA200-27.83% Trades Volume52,473 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-07-24Initiated H.C. Wainwright Buy $10
May-02-24Downgrade JP Morgan Overweight → Neutral $16 → $6
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13 '24Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09 '24Buy10.25100,0001,025,000100,000Feb 15 08:38 PM